efficacy of glp 1 receptor agonists Pharmacological interventions for obesity in patients with inflammatory bowel disease: A systematic review GLP-1 agonist and safety Glucagon-like peptide-1 (GLP-1) receptor agonists
Description
R., Cho, H
Governments in LMICs should consider incorporating GLP-1RAs into national essential medicines lists and negotiating tiered pricing with manufacturers
Further, it is worth highlighting that survodutide is likely to drive the market in the near future
Enrolled patients were randomized to once-daily oral Wegovy 25 mg or placebo, as an adjunct to lifestyle intervention for 64 weeks
